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ABSTRACT
Background: Non-steroidal anti-inflammatory drugs
(NSAIDs) and proton pump inhibitors (PPIs) are
regarded as two types of drugs that respectively
increase and decrease the risk of peptic ulcer bleeding.
However, their relation to occurrence, recurrence and
death of bleeding in the population level is not clear.
Study objective: To clarify recent calendar-time
correlations between sales of NSAIDs and PPIs and the
occurrence of peptic ulcer bleeding, re-bleeding and
death.
Design: Ecological study.
Results: The time trend of peptic ulcer bleeding did
not correlate with PPI sales but did correlate with
NSAIDs in mem (Rmale=0.6571, Pmale=0.05). Sales of
PPIs (inverse) and NSAIDs correlated with re-bleeding
in women (Rmale=−0.8754, Pmale=0.002 and
Rfemale=0.7161, Pfemale=0.03, respectively), but not in
men. An inverse correlation between PPI sales and 30-
day death after bleeding was found (Rmale=−0.9392,
Pmale=0.0002 and Rfemale=−0.8561, Pfemale=0.003), and
NSAID sales were found to correlate with increased
death after bleeding ((Rmale=0.7278, Pmale=0.03,
Rfemale=0.7858, Pfemale=0.01).
Conclusions: The sales of NSAIDs and PPIs correlate
with recurrence of peptic ulcer bleeding in women and
death after peptic ulcer bleeding in both genders in the
population level.
INTRODUCTION
Bleeding is one of the most frequent and
serious complications of peptic ulcer disease.
Despite the marked decrease in the occur-
rence of peptic ulcer disease during recent
decades, paralleling the decreasing prevalence
of Helicobacter pylori infection, the incidence of
peptic ulcer bleeding has not changed appar-
ently. On the contrary, several surveys have
shown that the incidence of peptic ulcer bleed-
ing has increased among older people.1–4
Re-bleeding and death after peptic ulcer
bleeding occur in 7–16% and 3–14%,2 5 6
respectively. These figures might increase as a
result of the increasing average age of many
populations.1 2 7 8 The high risk of recurrence
and death highlights the need to identify the
best preventive measures available. The estab-
lished risk factors for peptic ulcer bleeding
include H pylori infection and medications
such as non-steroidal anti-inflammatory drugs
(NSAIDs), whereas proton pump inhibitors
ARTICLE SUMMARY
Article focus
Non-steroidal anti-inflammatory drugs (NSAIDs)
and proton pump inhibitors (PPIs) are two types of
drugs that are closely associated with opposite risk
of peptic ulcer bleeding. Their relation to occur-
rence, recurrence and death of bleeding in the
population level is not clear.
Key messages
▪ The sales of NSAIDs and PPIs (inversely) correl-
ate with recurrence and death after peptic ulcer
bleeding on the population level.
▪ Women appeared to have a higher fatality of
bleeding which might be associated with older
age and higher sales of NSAIDs.
▪ The results highlight the need for careful consid-
eration of drug prescriptions to patients with
peptic ulcer bleeding.
Strengths and limitations
▪ Drug sales/use and peptic bleeding outcomes
could not be linked with regard to individual
patients.
▪ Re-bleeding could only be identified on the basis
of re-admission, which means we might have
lost information regarding re-bleeding that
occurred within the same case of hospitalisation.
▪ It is difficult to find a suitable cut-off day for def-
inition of re-bleeding.
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(PPIs) can prevent ulcer bleeding.9 We aimed to examine
how the sales of PPIs and NSAIDs correlate with the inci-
dence, recurrence and death of peptic ulcer bleeding
from a population perspective.
METHODS
Study design
This was a nationwide ecological study that addressed
the correlation between relevant drug sales and peptic
ulcer bleeding in Sweden during the period 2000–2008.
We used complete Swedish nationwide registers to
collect data on sales of NSAIDs and PPIs, hospitalisation
and death after peptic ulcer bleeding. The average daily
defined doses (DDDs) of NSAIDs and PPIs were com-
pared with the incidence, recurrence within 60 days
after hospitalisation for bleeding, and 30-day death after
admission for peptic ulcer bleeding, in Sweden. The
Regional Ethics Committee in Stockholm approved the
study.
Data collection
Aggregated data on drug sales in Sweden during the
study period were available from the Swedish Prescribed
Drug Register. This register records all prescribed and
collected medications in the entire Swedish population
of approximately 9 million inhabitants.10 The Prescribed
Drug Register contains data on the age and sex of
patients together with the names of prescribed drug sub-
stances according to the anatomical therapeutic chem-
ical (ATC) classification. All NSAIDs (ATC codes: M01A)
and PPIs (ATC codes: A02BC and A02BD) were used for
this study. All NSAIDs with ATC codes of M01A were
sold as prescription drugs except a few types of ibupro-
fen in Sweden.
Patients with peptic ulcer bleeding were identified
from the Swedish Patient Register, which contains com-
plete, nationwide data on all codes representing diagno-
ses and surgical procedures relating to inhospital care in
Sweden since 1987. Codes representing peptic ulcer
bleeding according to the international classification of
diseases V.10 were used (K25.0, K25.4, K26.0, K26.4,
K27.0, K27.4, K28.0, K28.4, K92.0, K92.1 and K92.2).
Since the treatment of ulcer perforation is different
from the treatment of ulcer bleeding, patients with per-
foration were excluded. Re-admission for peptic ulcer
bleeding within 1 day of discharge was not regarded as a
new case of bleeding. Re-bleeding was defined as an
episode of bleeding that occurred within 60 days after a
previous bleeding. Death was defined as any death
occurring within 30 days of the date of admission for
peptic ulcer bleeding. Death dates were obtained from
the Death of Cause Register and the Swedish Population
Register. The personal number, which is the unique
identity for all the Swedish residents, was used to link
data among different registers.
Statistical analyses
Average DDD and time trends regarding the sales of
PPIs and NSAIDs were calculated on the basis of the
average population for each year. DDD/TID was
described as DDDs/thousand inhabitants/day. A linear
regression model was applied to test the statistical signifi-
cance of trends at the 5% level. Correlation analyses
were performed between drug sales and the incidence,
recurrence and death of peptic ulcer bleeding. All ana-
lyses were gender-specific. Figures were plotted to show
the correlations between drug sales and bleeding events.
All statistical analyses were performed using SAS V.9.2
(SAS Institute, Cary, North Carolina, USA).
RESULTS
Trends of PPI and NSAID sales
The sales of PPIs increased during the study period,
except for a temporary drop in 2003 (figure 1). The
sales of NSAIDs increased until 2004, after which there
was a decrease to a level lower than in the year 2000
(figure 2). The decreased NSAID sales were particularly
evident in patients over 75 years of age (data not
shown). Women bought more PPIs and NSAIDs than
men (figures 1 and 2), and this difference was more
Figure 1 Sales of proton pump inhibitors (PPIs) in daily defined doses (DDDs)/1000 inhabitants/day and hospitalisation rate for
peptic ulcer bleeding (hospitalisations for bleeding/100 000 inhabitants) in Sweden in 2000–2008. (A and B) Represent men and
women, respectively.
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obvious with regard to NSAIDs. We also analysed the
trend of sales of aspirin and H2 receptor antagonists
(data not shown) which seems not very relevant with
trends of peptic ulcer bleeding, then we focused on cor-
relations of PPIs/NSAIDs and peptic ulcer bleeding in
this study.
Incidence, recurrence and death of peptic ulcer bleeding
The hospitalisation rate for peptic ulcer bleeding was
stable during the study period, although a higher rate
was observed in men than in women (figure 1). The rate
of recurrence of bleeding was similar between the
genders, although the recurrence rate in women showed
a slightly decreasing trend (figure 3). Thirty-day death
after peptic ulcer bleeding decreased during the study
period, especially in men (figures 5 and 6). Furthermore,
women showed a higher death rate in different time
periods (figure 6).
PPIs and NSAIDs sales and peptic ulcer bleeding
The trend of peptic ulcer bleeding did not correlate with
PPIs sales in either gender (figure 1; Rmale=−0.2274,
Pmale=0.5562, Rfemale=−0.2398, Pfemale=0.5342), but it cor-
related marginally with the trend of the sales of NSAIDs
in men only (figure 2; Rmale=0.6571, Pmale=0.05,
Pfemale=0.2633, Rfemale=0.4177).
PPI and NSAID sales and peptic ulcer re-bleeding
The time trends of re-bleeding did not correlate with the
sales of PPIs or NSAIDs in men (figures 3 and 4,
Rmale=0.2227, Pmale=0.5647; Rfemale=0.023, Pfemale=0.9522),
but the decreased occurrence of re-bleeding in women
correlated with the time trends of both PPI sales (Rmale=
−0.8754, Pmale=0.002) and NSAID sales (Rfemale=0.7161,
Pfemale=0.03).
PPI and NSAID sales and 30-day death
There was an inverse correlation between PPI sales and
death in both genders (Rmale=−0.9392, Pmale=0.0002,
Rfemale=−0.8561, Pfemale=0.003; figure 4), and the NSAID
sales showed a close correlation with death of bleeding in
both genders (Rmale=0.7278, Pmale=0.03, Rfemale=0.7858,
Pfemale=0.01; figure 5).
DISCUSSION
This study indicates that sales of NSAIDs and PPIs
(inversely) correlates with 30-day death (both sexes) and
recurrence (womenfemales) of peptic ulcer bleeding in
Figure 2 Sales of non-steroidal anti-inflammatory drugs (NSAIDs) in daily defined doses (DDD)/1000 inhabitants/day and
hospitalisation rate for peptic ulcer bleeding (hospitalisations for bleeding per 100 000 inhabitants) in Sweden in 2000–2008. (A and
B) Represent men and women, respectively.
Figure 3 Sales of proton pump inhibitors (PPIs) in daily defined doses (DDDs)/1000 inhabitants/day and peptic ulcer
re-bleeding rate within 60 days (number of re-bleeders/100 inhospitalisations for bleeding) in Sweden in 2000–2008. (A and B)
Represent men and women, respectively.
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the unselected population. Women appeared to have a
higher death of bleeding which might be associated with
age and greater sales/use of NSAIDs.
The main strength of this study is the nationwide,
complete data collection regarding drug sales, hospital-
isation for bleeding and death. Since there is virtually
no private care for peptic ulcer bleeding in Sweden and
since such bleeding usually requires hospitalisation, the
incidence of bleeding and re-bleeding covered by this
study should represent population-based figures. There
are, however, several weaknesses that should be acknowl-
edged. Drug sales/use and peptic bleeding outcomes
could not be linked with regard to individual patients.
This ecological design makes the interpretations more
uncertain. Re-bleeding could only be identified on the
basis of re-admission, which means we might have lost
information regarding re-bleeding that occurred within
the same case of hospitalisation. On the other hand, it is
difficult to find a suitable cut-off day for definition of
re-bleeding. The definition of death of bleeding was
based on death within 30 days after discharge, since it is
difficult to assess if death actually results from bleeding.
Furthermore, selection bias for PPIs users could exist
since PPIs were also prescribed for gastroesophageal
reflux diseases. This might dilute the correlation
between PPIs and incidence of peptic ulcer bleeding.
Nevertheless, we also have studied correlation between
PPIs/NSAIDs and re-bleeding, PPIs/NSAIDs and mortal-
ity after bleeding diagnosis which may possibly further
pinpoint the specific correlation between PPIs/NSAIDs
and peptic ulcer bleeding. In addition, a few types of ibu-
profen as one of NSAIDs were sold as over-the-counter
drugs which might lead to selection bias for NSAIDs in
this study. Since most NSAIDs were prescribed drugs and
actually few persons buy drugs without prescriptions in
Sweden due to the nationwide healthcare system, this
selection bias may be negligible.
NSAIDs constitute an established risk factor for peptic
ulcer bleeding, but the sales/use of these medications at
the population level is less well-documented. A previous
study reported that the sales of NSAIDs in Sweden
increased during the period 1978–2002.11 The present
study shows that sales have decreased since 2004 with
regard to both genders, and this decrease is more
obvious in women and in the population aged over 75
(data not shown). This decline might contribute to the
decreasing trend of peptic ulcer death and re-bleeding
in women. Similarly, the increased sales/use of PPIs
Figure 4 Sales of proton pump inhibitors (PPIs) in daily defined doses (DDDs)/1000 inhabitants/day and 30-day death of peptic ulcer
bleeding (number of deaths within 30 days/100 hospitalisations for bleeding) in Sweden 2000–2008. (A and B) Represent men and
women, respectively.
Figure 5 Sales of non-steroidal anti-inflammatory drugs (NSAIDs) in daily defined doses (DDDs)/1000 inhabitants/day and 30-day
death of peptic ulcer bleeding (number of deaths within 30 days per 100 hospitalisations for bleeding) in Sweden in 2000–2008. (A and
B) Represent men and women, respectively.
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might contribute to these trends. The correlation
between sales/use of PPIs and death indicates that PPIs
might prevent deaths from bleeding. This relation is
more apparent in the male population, which shows a
very interesting, coinciding pattern. The different corre-
lations of drug and bleeding death between men and
women could be attributed to the different sales/use of
PPIs and NSAIDs between the genders. Previous studies
have found that PPIs may help reduce peptic ulcer
bleeding, re-bleeding and the need for surgery, but not
death.12–14 It is difficult to differentiate between the
respective roles of PPIs and NSAIDs. Nevertheless, the
gastric mucosal protective effects of PPIs could be bene-
ficial if NSAIDs are used. Surprisingly, PPIs are used in
only 10–22% of patients admitted with a peptic ulcer
disease and using NSAIDs.15–17 Our recent study, using
individual prescription data from Sweden, revealed that
less than 40% long-term NSAIDs users (those prescribed
NSAIDs for more than 180 days) were prescribed con-
comitantly gastroprotective medication.18 Furthermore,
this study found that men took less gastroprotective
drugs compared with women, despite the fact that con-
comitant antithrombotic treatment was more common
in men. On the other side, a German study found that
overprescription of drugs might increase risk of adverse
effect because of drug–drug interactions.19 It may indi-
cate that the use of NSAIDs in high-risk population, for
example, patients with a history of complicated peptic
ulcer and elderly population with several concomitant
prescriptions, should be cautious, and a personalised
regimen should be considered thoroughly.
The incidence of peptic ulcer bleeding is higher in
men than in women, but few studies have reported
gender distribution with regard to re-bleeding and
death. One British case series study suggested that
women are at a higher risk of perforation or death than
men.20 The older mean age in women was, however, an
important factor in that study, and this is consistent with
our data (data not shown). The greater sales/use of
NSAIDs in women cannot be ignored. The rapid
decrease of NSAID sales/use in women, since 2004,
might contribute to the significantly decreased occur-
rence of re-bleeding and death in this group in which
PPI sales/use is increasing continuously.
In conclusion, although the sales/use of NSAIDs and
PPIs in the general population does not seem to mirror
the incidence of peptic ulcer bleeding, such sales/use
correlate with re-bleeding and death of peptic ulcer
bleeding. This correlation seems more obvious in old
women which proposes an intriguing issue for future
study. The potential reduced risk of death due to
decreased use of NSAIDs (especially in old women) and
increased use of PPIs (especially in men) warrants
further investigation.
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